GLP-1 drug manufacturers face nearly 100 lawsuits alleging the medications caused vision loss through a rare eye condition called NAION. While some research suggests a potential link, other studies found no association, and health authorities say evidence remains insufficient to establish causation. Novo Nordisk and Eli Lilly deny any significant relationship between their drugs and the condition.
Hundreds of consumers are suing manufacturers of GLP-1 weight-loss drugs, claiming they cause NAION, a rare eye condition leading to sudden vision loss. Research shows mixed results with some studies finding increased NAION risk in semaglutide users, though observational evidence cannot prove causation, and regulatory agencies remain under investigation without issuing formal warnings.